New Dental Treatment Helps Fill Cavities and Insurance Gaps for Seniors

DENVER ― Dental hygienist Jennifer Geiselhofer often cleans the teeth of senior patients who can’t easily get to a dentist’s office. But until recently, if she found a cavity, there was little she could do.

“I can’t drill. I can’t pull teeth,” said Geiselhofer, whose mobile clinic is called Dental at Your Door. “I’d recommend they see a dentist, but that was often out of the question because of mobility challenges. So visit after visit, I would come back and there would be more decay.”

But now Geiselhofer has a weapon to obliterate a cavity with a few brushstrokes.

Silver diamine fluoride is a liquid that can be painted on teeth to stop decay. Fast, low-cost and pain-free, the treatment is rapidly gaining momentum nationwide as the cavity treatment of choice for patients who can’t easily get a filling, such as the very young or the very old.

“It has been life-changing for my patients,” said Geiselhofer, who has been using the treatment for about 18 months.

Geiselhofer has not been able to go into nursing homes during the COVID-19 pandemic, but she uses the liquid on the older adults she visits in private homes. She also uses it to treat the cavities of patients in homeless shelters, jails and Head Start programs ― now wearing greater protective gear, including gloves, a surgical mask, an N95 mask and a face shield.

The topical medication is an especially good option for seniors, dental industry experts say, because dental care has remained a major gap in health insurance coverage despite poor dental hygiene being linked to heart disease and other health problems like diabetes and pneumonia. Medicare doesn’t cover most dental care, and patients on a fixed income often can’t afford treatment. But because of the effectiveness and low cost of silver diamine fluoride, more state Medicaid programs now cover it — and older adults who pay out-of-pocket can afford it outright.

Silver diamine fluoride has been used in other countries for decades, and studies have proved it safe. Its biggest downside is that it permanently turns the decayed area black — a turnoff, in particular, for people with decay on a front tooth.

Dental providers say the black spots can be covered by tooth-colored material for an extra cost. For older adults, Geiselhofer said, a dark spot is a small price to pay for a treatment that stops cavities quickly, with no drilling, needle prick or trip to the dentist required.

Oral Care a Problem for Older Adults

Silver diamine fluoride was approved by the Food and Drug Administration in 2014 for reducing tooth sensitivity. But its off-label use to treat cavities was quickly adopted. It made headlines as a trauma-free treatment for tooth decay in children under age 5.

Pediatric dentists have embraced it as a solution for kids who can’t sit still for treatment and whose parents want to avoid general anesthesia. In 2018, the then-president of the American Academy of Pediatric Dentistry, James Nickman, said that, aside from fluoridated water, the topical cavity fighter “may be the single greatest innovation in pediatric dental health in the last century.”

But today, with more older Americans keeping their natural teeth than in decades past, the treatment is also serving as a boon for a different generation. Because of insurance gaps and the prohibitive cost of most dental treatments, many seniors miss out on preventive care to stave off dental decay, putting them at risk for dental disease that can trigger serious health problems. About 27% of Americans age 65 and older have untreated cavities, according to the Centers for Disease Control and Prevention.

Residents in long-term care facilities are at especially high risk, studies show. Medications cause their mouths to dry, promoting decay. They also may have cognitive issues that make it difficult to practice good oral care. And many are either too frail for traditional dental treatment or too weak to be transported.

Dental Hygienists Lead the Way

Take 87-year-old Ron Hanscom, for example. A patient of Geiselhofer’s, he has been in a Denver nursing home since he had a stroke six years ago, and needs a mechanical lift to get into and out of his wheelchair.

On a visit to Hanscom’s nursing home earlier this year, before the pandemic, Geiselhofer spotted a cavity under one of his crowns. After checking in with his dentist, she used a small brush to paint on the silver treatment.

“It’s a good thing she had the silver, because I couldn’t get to a dentist’s office — no way,” Hanscom said. “She did it right in my room.”

Across the country, dental hygienists provide much of the care to patients like Hanscom who otherwise might never see a dentist. They also see patients in homeless shelters, schools, jails and low-cost medical clinics. Since the pandemic hit, Geiselhofer said she has received a flood of requests for in-home care from seniors who are too nervous to go into a dentist’s office, but she has turned them down because she is too busy caring for underserved populations.

Many states allow hygienists to work directly with patients in public health settings without a dentist’s supervision, and Colorado is one of a few that allows them to set up a completely independent practice.

Because the silver treatment is relatively new in this country and can leave a stain, the Colorado state legislature passed a law in 2018 that says hygienists must have an agreement with a supervising dentist to apply it. The law also requires them to get special training on how to use the liquid, which at least 700 hygienists from across the state have completed.

Other states, including Maryland and Virginia, have no special requirements for applying the cavity treatment but require some supervision by a dentist, said Matt Crespin, president of the American Dental Hygienists’ Association. In those places, hygienists apply it under the same rules that govern the application of other fluoride products.

Preventing New Cavities, Too

Studies show silver diamine fluoride stops decay in 60% to 70% of cases with one application. A second application six months later boosts the treatment’s long-term effectiveness to more than 90%.

In addition to killing cavity-causing bacteria, the treatment hardens tooth structure, desensitizes the tooth and even stops new cavities from forming. Applying the liquid on the exposed root surfaces of older adults once a year is “a simple, inexpensive, and effective way” to prevent cavities, a 2018 study concluded.

One of the most important benefits of the application on older patients is that the liquid can reach decay that forms under existing dental work such as crowns and bridges, said dental hygienist Michelle Vacha, founder of Community Dental Health, which runs clinics in Colorado Springs and Pueblo, Colorado.

Previously, a dentist would have had to remove the crown, drill out the cavity and make a new crown — a traumatic, time-consuming procedure with a typical cost of $1,000 or more, Vacha said. Unable to afford the cost, many patients would instead have the tooth pulled.

The paint-on liquid is significantly cheaper than traditional treatment. Estimates vary, but a private dentist may charge $10 to $75 for one application, compared with $150 to $200 for a filling. Hygienists often have lower fees. At Vacha’s community clinics, the cost is $10 a tooth.

About half of state Medicaid programs now reimburse for the treatment, said Steve Pardue, scientific officer of Elevate Oral Care that distributes Advantage Arrest, the main brand of the topical medication used nationally. Reimbursement rates range from $5 to $75 per application.

More private insurers — about 20% to 30% of them — have also started covering it, Pardue said.

Coming Soon to a Dentist Near You?

A small but growing number of mainstream dentists have begun to offer the treatment to all patients, not just the youngest and oldest.

It’s a good option for those who have anxiety about dental work or concerns about cost, said Dr. Janet Yellowitz, director of geriatric and special care dentistry at the University of Maryland School of Dentistry.

A 2017 survey by the American Dental Association found that almost 8 in 10 dentists had never used the treatment. The ADA doesn’t have more recent statistics, but ADA spokesperson Matthew Messina said anecdotal reports indicate usage is increasing dramatically.

Yellowitz noted that dentists still have a financial incentive to drill and fill. She has made presentations highlighting the benefits of the silver solution at national conferences.

“We’re trying to get everyone to use it,” she said. “It’s a slow process because we’re asking dentists who have been trained for their whole careers to do things one way to completely change their mentality. It’s like asking them to go to another country and drive on the other side of the road.”


This story was produced by Kaiser Health News, an editorially independent program of the Kaiser Family Foundation.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

USE OUR CONTENT

This story can be republished for free (details).

Tough to Tell COVID From Smoke Inhalation Symptoms — And Flu Season’s Coming

The patients walk into Dr. Melissa Marshall’s community clinics in Northern California with the telltale symptoms. They’re having trouble breathing. It may even hurt to inhale. They’ve got a cough, and the sore throat is definitely there.

A straight case of COVID-19? Not so fast. This is wildfire country.

Up and down the West Coast, hospitals and health facilities are reporting an influx of patients with problems most likely related to smoke inhalation. As fires rage largely uncontrolled amid dry heat and high winds, smoke and ash are billowing and settling on coastal areas like San Francisco and cities and towns hundreds of miles inland as well, turning the sky orange or gray and making even ordinary breathing difficult.

But that, Marshall said, is only part of the challenge. Facilities already strapped for testing supplies and personal protective equipment must first rule out COVID-19 in these patients, because many of the symptoms they present with are the same as those caused by the virus.

“Obviously, there’s overlap in the symptoms,” said Marshall, the CEO of CommuniCare, a collection of six clinics in Yolo County, near Sacramento, that treats mostly underinsured and uninsured patients. “Any time someone comes in with even some of those symptoms, we ask ourselves, ‘Is it COVID?’ At the end of the day, clinically speaking, I still want to rule out the virus.”

The protocol is to treat the symptoms, whatever their cause, while recommending that the patient quarantine until test results for the virus come back, she said.

It is a scene playing out in numerous hospitals. Administrators and physicians, finely attuned to COVID-19’s ability to spread quickly and wreak havoc, simply won’t take a chance when they recognize symptoms that could emanate from the virus.

“We’ve seen an increase in patients presenting to the emergency department with respiratory distress,” said Dr. Nanette Mickiewicz, president and CEO of Dominican Hospital in Santa Cruz. “As this can also be a symptom of COVID-19, we’re treating these patients as we would any person under investigation for coronavirus until we can rule them out through our screening process.” During the workup, symptoms that are more specific to COVID-19, like fever, would become apparent.

For the workers at Dominican, the issue moved to the top of the list quickly. Santa Cruz and San Mateo counties have borne the brunt of the CZU Lightning Complex fires, which as of Sept. 10 had burned more than 86,000 acres, destroying 1,100 structures and threatening more than 7,600 others. Nearly a month after they began, the fires were approximately 84% contained, but thousands of people remained evacuated.

Dominican, a Dignity Health hospital, is “open, safe and providing care,” Mickiewicz said. Multiple tents erected outside the building serve as an extension of its ER waiting room. They also are used to perform what has come to be understood as an essential role: separating those with symptoms of COVID-19 from those without.

At the two Solano County hospitals operated by NorthBay Healthcare, the path of some of the wildfires prompted officials to review their evacuation procedures, said spokesperson Steve Huddleston. They ultimately avoided the need to evacuate patients, and new ones arrived with COVID-like symptoms that may actually have been from smoke inhalation.

Huddleston said NorthBay’s intake process “calls for anyone with COVID characteristics to be handled as [a] patient under investigation for COVID, which means they’re separated, screened and managed by staff in special PPE.” At the two hospitals, which have handled nearly 200 COVID cases so far, the protocol is well established.

Hospitals in California, though not under siege in most cases, are dealing with multiple issues they might typically face only sporadically. In Napa County, Adventist Health St. Helena hospital evacuated 51 patients on a single August night as a fire approached, moving them to 10 other facilities according to their needs and bed space. After a 10-day closure, the hospital was allowed to reopen as evacuation orders were lifted, the fire having been contained some distance away.

The wildfires are also taking a personal toll on health care workers. CommuniCare’s Marshall lost her family’s home in rural Winters, along with 20 acres of olive trees and other plantings that surrounded it, in the Aug. 19 fires that swept through Solano County.

“They called it a ‘firenado,’” Marshall said. An apparent confluence of three fires raged out of control, demolishing thousands of acres. With her family safely accounted for and temporary housing arranged by a friend, she returned to work. “Our clinics interact with a very vulnerable population,” she said, “and this is a critical time for them.”

While she pondered how her family would rebuild, the CEO was faced with another immediate crisis: the clinic’s shortage of supplies. Last month, CommuniCare got down to 19 COVID test kits on hand, and ran so low on swabs “that we were literally turning to our veterinary friends for reinforcements,” the doctor said. The clinic’s COVID test results, meanwhile, were taking nearly two weeks to be returned from an overwhelmed outside lab, rendering contact tracing almost useless.

Those situations have been addressed, at least temporarily, Marshall said. But although the West Coast is in the most dangerous time of year for wildfires, generally September to December, another complication for health providers lies on the horizon: flu season.

The Southern Hemisphere, whose influenza trends during our summer months typically predict what’s to come for the U.S., has had very little of the disease this year, presumably because of restricted travel, social distancing and face masks. But it’s too early to be sure what the U.S. flu season will entail.

“You can start to see some cases of the flu in late October,” said Marshall, “and the reality is that it’s going to carry a number of characteristics that could also be symptomatic of COVID. And nothing changes: You have to rule it out, just to eliminate the risk.”

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

USE OUR CONTENT

This story can be republished for free (details).

Es difícil decir si es COVID, síntomas por inhalar humo… o la gripe que ya llega

[khn_slabs slabs=”260982″ view=”pull-right” /]

Los pacientes entran en las clínicas comunitarias de la doctora Melissa Marshall, en el norte de California, con síntomas reveladores. Tienen problemas para respirar, tos, y dolor de garganta.

¿Un caso claro de COVID-19? No tan rápido. Esta es una región de incendios forestales.

[khn_slabs syndicated=”863440″ view=”pull-right” /]

A lo largo de la costa oeste, hospitales y centros de salud reportan pacientes con problemas relacionados con la inhalación de humo.

A medida que los incendios se propagan de forma descontrolada, por el calor seco y los fuertes vientos, el humo y las cenizas se expanden y se asientan en zonas costeras como San Francisco, y en ciudades y pueblos a cientos de kilómetros tierra adentro, haciendo que el cielo se vuelva naranja o gris y dificultando incluso la respiración normal.

Pero eso, dijo Marshall, es sólo una parte del desafío. Los centros, que ya están al límite de suministros para hacer pruebas y de equipos de protección personal (EPP), deben descartar primero la presencia de COVID-19 en estos pacientes, porque muchos de los síntomas que presentan son los mismos que los que causa el virus.

“Obviamente, existe una coincidencia en los síntomas”, señaló Marshall, que es CEO de CommuniCare, una red de seis clínicas en el condado de Yolo, cerca de Sacramento, que trata principalmente a pacientes con poca cobertura o sin seguro médico. “Cada vez que alguien llega con algunos de esos síntomas, nos preguntamos, ‘¿Es COVID?’ Clínicamente hablando, debo descartar el virus”.

El protocolo es tratar los síntomas, cualquiera que sea su causa, y recomendar que el paciente se ponga en cuarentena hasta que lleguen los resultados de las pruebas del virus, afirmó Marshall.

Es una escena que se repite en numerosos hospitales. Administradores y médicos, atentos a la rápida propagación de COVID-19, no se arriesgan cuando observan síntomas que podrían revelar al virus.

“Hemos visto un aumento en el número de pacientes que llegan a la sala de emergencias con problemas respiratorios”, expresó la doctora Nanette Mickiewicz, presidenta y CEO del Dominican Hospital en Santa Cruz.

“Al llegar con síntomas que podrían ser de COVID-19, tratamos a estos pacientes como lo haríamos con cualquier persona sospechosa de coronavirus hasta que podamos descartarlos con nuestro proceso de detección”. Durante el proceso, los síntomas más específicos de COVID-19, como la fiebre, se harían evidentes.

Para los trabajadores de Dominican, el tema pronto se vivió con urgencia. Los condados de Santa Cruz y San Mateo han sido los más afectados por los incendios del CZU Lightning Complex, que hasta el 10 de septiembre habían quemado más de 86,000 acres, destruyendo 1,100 edificios y amenazando a otros 7,600. Casi un mes después de que comenzaran, los incendios fueron contenidos en un 84%, pero miles de personas permanecían evacuadas.

Dominican, un hospital de Dignity Health, permanece “abierto, es seguro y proporciona atención médica”, aseguró Mickiewicz. Múltiples tiendas de campaña, levantadas en el exterior del centro, sirven como una extensión de la sala de espera para el servicio de Urgencias. También se utilizan para llevar a cabo lo que se considera una función esencial: separar a los que tienen síntomas de COVID-19 de los que no.

En los dos hospitales del condado de Solano, operados por NorthBay Healthcare, la trayectoria de algunos de los incendios forestales llevó a los funcionarios a revisar sus procedimientos de evacuación, explicó el vocero Steve Huddleston. Al final, no hubo necesidad de evacuar a los pacientes, y los nuevos llegaron con síntomas parecidos a los de COVID que, en realidad, podían deberse a la inhalación de humo.

Huddleston dijo que el proceso de admisión de NorthBay “requiere que cualquier persona con síntomas de COVID se considere sospechosa para el coronavirus, lo que significa que son separados, examinados y manejados por personal con EPP”.

En los dos hospitales, que hasta ahora han tratado casi 200 casos de COVID, el protocolo está bien establecido.

Los hospitales de California, aunque en su mayoría no están saturados, se enfrentan a múltiples problemas que normalmente sólo se presentan de forma esporádica.

En el condado de Napa, el hospital Adventist Health St. Helena evacuó a 51 pacientes en una sola noche de agosto ante la cercanía del fuego, trasladándolos a otros 10 centros según sus necesidades y la disponibilidad de camas. Tras un cierre de 10 días, se permitió la reapertura del hospital al finalizar las órdenes de evacuación, ya que el incendio se había contenido.

Los incendios forestales también afectan de manera personal a los trabajadores de salud. La doctora Marshall, de CommuniCare, perdió la casa de su familia en la zona rural de Winters, junto con 20 acres de olivos y otras plantaciones que la rodeaban, en los incendios del 19 de agosto que arrasaron el condado de Solano.

“Lo llamaron un ‘fogonazo’”, contó Marshall. Una confluencia de tres incendios que se desató fuera de control, arrasando miles de acres. Con su familia a salvo y una vivienda temporal proporcionada por un amigo, volvió al trabajo. “Nuestras clínicas interactúan con una población muy vulnerable”, dijo, “y este es un momento crítico para ellos”.

Mientras pensaba en cómo reconstruiría su hogar, la doctora debió enfrentarse a otra crisis: la escasez de suministros de la clínica. El mes pasado, CommuniCare sólo contaba con 19 kits para pruebas de COVID, y la escasez de hisopos era tal “que literalmente nos dirigimos a nuestros amigos veterinarios en busca de refuerzos”, explicó.

Mientras tanto, los resultados de las pruebas de COVID de la clínica tardaban casi dos semanas en llegar, desde un abrumado laboratorio exterior, haciendo que el rastreo de contactos fuera casi inútil.

Esas situaciones ya están controladas, al menos temporalmente, aseguró Marshall. Y aunque la Costa Oeste se encuentra en la época más peligrosa del año para los incendios forestales, generalmente de septiembre a diciembre, ahora surge otra complicación para los proveedores de salud: la temporada de gripe.

Las tendencias de la temporada de gripe en el hemisferio sur, que coincide con nuestros meses de verano, por lo general predicen lo que nos espera en los Estados Unidos. Pero este año, se ha visto muy poco de la enfermedad, presumiblemente debido a la restricción de los viajes, el distanciamiento social y el uso de máscaras. Y es demasiado pronto para saber lo que traerá la temporada de gripe a los Estados Unidos.

“Se pueden empezar a ver algunos casos de gripe a finales de octubre”, apuntó Marshall, “y la realidad es que van a llegar con una serie de características que también podrían ser sintomáticas de COVID. Y nada cambia: tienes que descartarlo, para eliminar el riesgo”.

NIH and FDA Examine Serious Side Effect That Surfaced in COVID Vaccine Trial

The Food and Drug Administration is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case.

“The highest levels of NIH are very concerned,” said Dr. Avindra Nath, intramural clinical director and a leader of viral research at the National Institute for Neurological Disorders and Stroke, an NIH division. “Everyone’s hopes are on a vaccine, and if you have a major complication the whole thing could get derailed.”

A great deal of uncertainty remains about what happened to the unnamed patient, to the frustration of those avidly following the progress of vaccine testing. AstraZeneca, which is running the global trial of the vaccine it produced with Oxford University, said the trial volunteer recovered from a severe inflammation of the spinal cord and is no longer hospitalized.

AstraZeneca has not confirmed that the patient was afflicted with transverse myelitis, but Nath and another neurologist said they understood this to be the case. Transverse myelitis produces a set of symptoms involving inflammation along the spinal cord that can cause pain, muscle weakness and paralysis. Britain’s regulatory body, the Medicines and Healthcare Products Regulatory Agency, reviewed the case and has allowed the trial to resume in the United Kingdom.

AstraZeneca “need[s] to be more forthcoming with a potential complication of a vaccine which will eventually be given to millions of people,” said Nath. “We would like to see how we can help, but the lack of information makes it difficult to do so.”

Any decision about whether to continue the trial is complex because it’s difficult to assess the cause of a rare injury that occurs during a vaccine trial — and because scientists and authorities have to weigh the risk of uncommon side effects against a vaccine that might curb the pandemic.

“So many factors go into these decisions,” Nath said. “I’m sure everything is on the table. The last thing you want to do is hurt healthy people.”

The NIH has yet to get tissue or blood samples from the British patient, and its investigation is “in the planning stages,” Nath said. U.S. scientists could look at samples from other vaccinated patients to see whether any of the antibodies they generated in response to the coronavirus also attack brain or spinal cord tissue.

Such studies might take a month or two, he said. The FDA declined to comment on how long it would take before it decides whether to move forward.

Dr. Jesse Goodman, a Georgetown University professor and physician who was chief scientist and lead vaccine regulator at the FDA during the Obama administration, said the agency will review the data and possibly consult with British regulators before allowing resumption of the U.S. study, which had just begun when the injury was reported. Two other coronavirus vaccines are also in late-stage trials in the U.S.

If it determines the injury in the British trial was caused by the vaccine, the FDA could pause the trial. If it allows it to resume, regulators and scientists surely will be on the watch for similar symptoms in other trial participants.

A volunteer in an earlier phase of the AstraZeneca trial experienced a similar side effect, but investigators discovered she had multiple sclerosis that was unrelated to the vaccination, according to Dr. Elliot Frohman, director of the Multiple Sclerosis & Neuroimmunology Center at the University of Texas.

Neurologists who study illnesses like transverse myelitis say they are rare — occurring at a rate of perhaps 1 in 250,000 people — and strike most often as a result of the body’s immune response to a virus. Less frequently, such episodes have also been linked to vaccines.

The precise cause of the disease is key to the decision by authorities whether to resume the trial. Sometimes an underlying medical condition is “unmasked” by a person’s immune response to the vaccine, leading to illness, as happened with the MS patient. In that case, the trial might be continued without fear, because the illness was not specific to the vaccine.

More worrisome is a phenomenon called “molecular mimicry.” In such cases, some small piece of the vaccine may be similar to tissue in the brain or spinal cord, resulting in an immune attack on that tissue in response to a vaccine component. Should that be the case, another occurrence of transverse myelitis would be likely if the trial resumed, said Dr. William Schaffner, an infectious disease specialist at the Vanderbilt University School of Medicine. A second case would shut down the trial, he said.

In 1976, a massive swine flu vaccination program was halted when doctors began diagnosing a similar disorder, Guillain-Barré syndrome, in people who received the vaccine. At the time no one knew how common GBS was, so it was difficult to tell whether the episodes were related to the vaccine.

Eventually, scientists found that the vaccine increased the risk of the disorder by an additional one case among every 100,000 vaccinated patients. Typical seasonal flu vaccination raises the risk of GBS in about one additional case in every 1 million people.

“It’s very, very hard” to determine if one rare event was caused by a vaccine, Schaffner said. “How do you attribute an increased risk for something that occurs in one in a million people?”

Before allowing U.S. trials to restart, the FDA will want to see why the company and an independent data and safety monitoring board (DSMB) in the U.K. felt it was safe to continue, Goodman said. The AstraZeneca trial in the United States has a separate safety board.

FDA officials will need to review full details of the case and may request more information about the affected study volunteer before deciding whether to allow the U.S. trial to continue, Goodman said. They may also require AstraZeneca to update the safety information it provides to study participants.

It’s possible that the volunteer’s health problem was a coincidence unrelated to the vaccine, said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. Studies aren’t usually stopped over a single health problem, even if it’s serious.

Yet many health leaders have expressed frustration that AstraZeneca hasn’t released more information about the health problem that led it to halt its U.K. trial.

“There is just so little information about this that it’s impossible to understand what the diagnosis was or why the DSMB and sponsor were reassured” that it was safe to continue, Goodman said.

AstraZeneca has said it’s unable to provide more information about the health problem, saying this would violate patient privacy, although it didn’t say how.

But there’s an exceptional need for transparency in a political climate rife with vaccine hesitancy and mistrust of the Trump administration’s handling of the COVID-19 response, leading scientists say.

“While I respect the critical need for patient confidentiality, I think it would be really helpful to know what their assessment of these issues was,” Goodman said. “What was the diagnosis? If there wasn’t a clear diagnosis, what is it that led them to feel the trial could be restarted? There is so much interest and potential concern about a COVID-19 vaccine that the more information that can be provided, the more reassuring that would be.”

The FDA will need to balance any possible risks from an experimental vaccine with the danger posed by COVID-19, which has killed nearly 200,000 Americans.

“There are also potential consequences if you stop a study,” Goodman said.

If the AstraZeneca vaccine fails, the U.S. government is supporting six other COVID vaccines in the hope at least one will succeed. The potential problems with the AstraZeneca vaccine show this to be a wise investment, Adalja said.

“This is part of the idea of not having just one vaccine candidate going forward,” he said. “It gives you a little more insurance.”

Schaffner said researchers need to remember that vaccine research is unpredictable.

“The investigators have inadvisedly been hyping their own vaccine,” Schaffner said. “The Oxford investigators were out there this summer saying, ‘We’re going to get there first.’ But this is exactly the sort of reason … Dr. [Anthony] Fauci and the rest of us have been saying, ‘You never know what will happen once you get into large-scale human trials.’”

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

USE OUR CONTENT

This story can be republished for free (details).

‘It Seems Systematic’: Doctors Cite 115 Cases of Head Injuries From Crowd Control Devices

At least 115 people were injured this summer when police shot them in the head or neck with so-called “less-lethal” projectiles at protests over racial injustice and police brutality, according to a report published Monday.

It’s the most comprehensive tally of such injuries to date, with about twice as many victims as KHN and USA Today cited in a July examination of how police across the U.S. wielded the weapons to control crowds.

But Physicians for Human Rights, the organization that compiled the incidents, believes even its figures are an undercount because its analysis is based on publicly available data and excluded some reports without adequate evidence.

The organization identified Austin, Texas; Portland, Oregon; and Los Angeles as hot spots during the period studied, May 26 to July 27.

Abigail Rodas, who was shot in the jaw with a rubber bullet on May 30, was one of the victims in Los Angeles, according to a lawsuit filed against the city and the police chief on behalf of Black Lives Matter Los Angeles, the Los Angeles Community Action Network and 14 people, including six who were struck with projectiles.

According to the suit, Rodas was leaving a protest when she “was struck in the face by a projectile and momentarily lost consciousness.”

A steel plate was used to repair her jawbone, the lawsuit says. She couldn’t talk for about 10 days and could drink only liquids for a week, it says.

“Nearly three weeks after the injury, she has screws in her gums and rubber bands to immobilize her jaw while the bones rejoin,” the suit says.

The city denied the allegations in a court filing, saying any use of force “was reasonable and necessary for self-defense.”

Protests Shine Light on Use of ‘Less-Lethal’ Weapons

The sheer number of incidents in those two months was shocking, said Dr. Rohini Haar, lead investigator for the analysis and an emergency physician in Oakland, California.

“It seems systematic,” Haar said. “It seems like there needs to be a reckoning with the use of force in protests.”

The projectiles in question are often called “rubber bullets,” but in law enforcement they’re known as “kinetic impact projectiles.”

They include plastic projectiles tipped with hard sponge or foam, “bean bag” rounds that consist of fabric socks containing metal shot, and “Sting-Balls” — grenades that spray hard rubber pellets. The report also cites incidents in which tear gas canisters were fired at people.

Though the weapons are referred to as “less lethal,” Haar said, there should be a shift to language that acknowledges how dangerous they can be. “Weapons are just as lethal as somebody wants them to be,” she said.

A study published in 2017 in the medical journal BMJ Open, which Haar co-authored, found that 3% of people hit by projectiles worldwide died. Fifteen percent of the 1,984 people studied were permanently injured.

In a letter to the editor of the New England Journal of Medicine, a group of Austin doctors said 19 patients were treated for bean bag-related wounds at the downtown hospital closest to the protests over two days in late May.

For its analysis, Physicians for Human Rights searched social media, news accounts, lawsuits and other publicly available sources. They counted incidents on social media only if they were documented by photos or videos, and included news reports without visual evidence only from major newspapers or local affiliates of major outlets.

Physicians for Human Rights identified by name most of the people who were struck.

Among the group’s recommendations are banning weapons that release scattershot or multiple projectiles from a single canister because they can hit people indiscriminately, Haar said. Metal projectiles are particularly dangerous, she said.

She called for more training and adherence to departments’ rules on the use of such weapons.

“One of the findings of our study is police do not even appear to be following their own protocols for how to use these weapons or when,” Haar said.

There are no national standards for police use of less-lethal projectiles and no comprehensive data on their use, USA Today found.

Demonstrators in Los Angeles, Minneapolis, San Jose, Denver and Dallas told USA Today they were shot with less-lethal projectiles even though those departments don’t allow the weapons to be used against nonviolent people. Some witnesses said police aimed at faces or fired at close range.

Police have said they fired the weapons to protect themselves and property in chaotic, dangerous situations.

‘Protesters Feel Like They’re Being Attacked’

Haar, who has been studying these projectiles since 2014, said they have no place in crowd control. “Even before you get to the use of weapons, there needs to be a change in how we engage with protesters in terms of communication,” she said.

For example, police can get the phone number of a protest leader, opening the lines of communication. Police have other options besides firing projectiles, Haar said, such as “arresting the person that is actually violent, not just dispersing the entire crowd, or changing what you decide is an illegal assembly.”

Haar said the use of these projectiles tends to escalate tensions, “where the protesters feel like they’re being attacked.” Those who aren’t struck, she said, “are often incited. It’s not until that full crowd is dispersed that the anger goes away. The volatility has a cumulative impact that can last weeks or months.”

At least seven major U.S. cities and a few states have enacted or proposed limits on the use of less-lethal projectiles.

However, similar efforts have stalled in the face of opposition from police agencies or other critics. And as the summer stretched on, local and federal law enforcement agencies continued to use less-lethal weapons when confronting protesters.

Haar said city councils have reached out to her recently, showing they are “really trying to reckon with what they want in their communities.”

“I see more hope now than I have in all of my years of research,” she said. “I think the attention now is remarkable, and we actually have a really good chance of getting some actual, meaningful change.”

USA Today’s Kevin McCoy contributed to this report.


This story was produced by Kaiser Health News, an editorially independent program of the Kaiser Family Foundation.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

USE OUR CONTENT

This story can be republished for free (details).

Los NIH, “muy preocupados” por efectos secundarios en ensayo de vacuna para COVID

La Administración de Alimentos y Medicamentos (FDA) está evaluando la posibilidad de seguir a los reguladores británicos y reanudar el ensayo de la vacuna contra el coronavirus que se detuvo cuando un participante sufrió daño en la médula espinal. Incluso cuando los Institutos Nacionales de Salud (NIH) están investigando el caso.

“Los niveles más altos de los NIH están muy preocupados”, dijo el doctor Avindra Nath, director clínico y líder de investigación viral en el Instituto Nacional de Trastornos Neurológicos y Accidentes Cerebrovasculares, una división de los NIH.

“Las esperanzas de todos están en una vacuna, y si tienes una complicación importante, todo podría descarrilarse”, agregó.

Lo que le pasó a este paciente anónimo sigue siendo algo incierto, para frustración de quienes siguen con avidez el progreso de esta vacuna.

AstraZeneca, que está realizando el ensayo global de la vacuna que produjo junto con la Universidad de Oxford, dijo que el voluntario se recuperó de una inflamación severa de la médula espinal y que ya no está en el hospital.

AstraZeneca no ha confirmado que el paciente padeciera mielitis transversa, pero Nath y otro neurólogo dijeron que ese podría haber sido el caso. La mielitis transversa produce un conjunto de síntomas que involucran inflamación a lo largo de la médula espinal. Puede causar dolor, debilidad muscular y parálisis.

La Agencia Reguladora de Medicamentos y Productos Sanitarios, la autoridad británica similar a la FDA, revisó el caso y permitió que el ensayo se reanudara en el Reino Unido.

AstraZeneca “necesita ser más comunicativo con una posible complicación de una vacuna que eventualmente se administrará a millones de personas”, dijo Nath. “Nos gustaría ver cómo podemos ayudar, pero la falta de información lo dificulta”.

Cualquier decisión sobre si continuar un ensayo es compleja porque es difícil evaluar la causa de una lesión poco común que ocurre durante un estudio, y porque los científicos y las autoridades tienen que sopesar el riesgo de efectos secundarios poco comunes frente a una vacuna que podría frenar una pandemia.

“Son muchos los factores que intervienen en estas decisiones”, dijo Nath. “Lo último que quieres hacer es lastimar a las personas sanas”.

Los NIH aún tienen que obtener muestras de tejido o sangre del paciente británico, y su investigación está “en etapa de planificación”, dijo Nath.

Los científicos estadounidenses podrían analizar muestras de otros pacientes vacunados para ver si alguno de los anticuerpos que generaron en respuesta al coronavirus también ataca el tejido cerebral o de la médula espinal.

Estos estudios podrían llevar uno o dos meses, explicó. La FDA se negó a comentar sobre cuánto tiempo tomaría antes de decidir si seguir adelante.

El doctor Jesse Goodman, profesor de la Universidad Georgetown que fue científico jefe y principal regulador de vacunas de la FDA durante la administración Obama, dijo que la agencia revisará los datos y posiblemente consultará con sus pares británicos antes de permitir la reanudación del estudio en los Estados Unidos, que recién comenzaba cuando se reportó el problema.

Otras dos vacunas contra el coronavirus también se encuentran en la última etapa de ensayos en el país.

Si se determina que la lesión en el ensayo británico fue causada por la vacuna, la FDA podría cancelarlo. Si permite que se reanude, los reguladores y científicos seguramente estarán atentos a síntomas similares en otros participantes.

Una voluntaria en una fase anterior del ensayo de AstraZeneca experimentó un efecto secundario similar, pero los investigadores descubrieron que tenía esclerosis multiple, que no estaba relacionada con la vacunación, según el doctor Elliot Frohman, director del Centro de Esclerosis Múltiple y Neuroinmunología de la Universidad de Texas.

Los neurólogos que estudian enfermedades como la mielitis transversa dicen que son raras (ocurren a una tasa de quizás 1 de cada 250.000 personas) y atacan con mayor frecuencia como resultado de la respuesta inmunitaria del cuerpo a un virus. En menor grado, estos episodios también se han relacionado con las vacunas.

La causa precisa de la enfermedad es clave para decidir si reiniciar o no el ensayo. A veces, una condición médica subyacente se “desenmascara” por la respuesta inmune de una persona a la vacuna, como sucedió con la paciente con esclerosis múltiple. En ese caso, el ensayo podría continuar sin temor, porque la enfermedad no está relacionada con la vacuna.

Más preocupante es un fenómeno llamado “mimetismo molecular”. En tales casos, una pequeña porción de la vacuna puede ser similar al tejido del cerebro o la médula espinal, lo que da como resultado un ataque inmunológico en ese tejido en respuesta a un componente de la vacuna.

Si ese fuera el caso, sería probable otra aparición de mielitis transversa si se reanudara el ensayo, dijo el doctor William Schaffner, especialista en enfermedades infecciosas de la Escuela de Medicina de la Universidad de Vanderbilt. Un segundo caso cerraría el ensayo, expresó.

En 1976, un programa masivo de vacunación contra la influenza porcina se detuvo cuando los médicos comenzaron a diagnosticar un trastorno similar, el síndrome de Guillain-Barré, en personas que habían recibido la vacuna. En ese momento nadie sabía qué tan común era, por lo que era difícil saber si los episodios estaban relacionados con la vacuna.

Finalmente, los científicos descubrieron que la vacuna aumentaba el riesgo del trastorno en un caso adicional por cada 100.000 pacientes vacunados. La vacunación típica contra la influenza estacional aumenta el riesgo de contraer GBS en aproximadamente un caso adicional por cada millón de personas.

“Es muy, muy difícil” determinar si un evento raro fue causado por una vacuna, dijo Schaffner. “¿Cómo atribuyes un mayor riesgo de algo que ocurre en una persona en un millón?”.

Antes de permitir que se reinicien los ensayos en los Estados Unidos, la FDA querrá ver por qué la compañía y una junta independiente de monitoreo en el Reino Unido decidieron que era seguro continuar, dijo Goodman. El ensayo de AstraZeneca en los Estados Unidos tiene una placa de seguridad separada.

Los funcionarios de la FDA deberán revisar todos los detalles del caso y pueden solicitar más información sobre el voluntario del estudio afectado antes de decidir si permitir que continúe el ensayo en el país, dijo Goodman. También pueden requerir que AstraZeneca actualice la información de seguridad que proporciona a los participantes del estudio.

Es posible que el problema de salud del voluntario fuera una coincidencia no relacionada con la vacuna, dijo el doctor Amesh Adalja, investigador principal del Johns Hopkins Center for Health Security. Por lo general, los estudios no se detienen por un solo problema de salud, incluso si es grave.

Muchos líderes de salud han expresado su frustración porque AstraZeneca no ha publicado más información sobre el problema de salud que lo llevó a detener su ensayo en el Reino Unido.

AstraZeneca argumentó que dar más información violaría la privacidad del paciente, aunque no aclaró de qué manera.

Pero existe una necesidad excepcional de transparencia en un clima político plagado de vacilaciones sobre las vacunas y desconfianza en el manejo de la respuesta a COVID-19 de la administración Trump, dicen científicos.

“Si bien respeto la necesidad crítica de confidencialidad del paciente, creo que sería realmente útil saber cuál fue su evaluación de estos problemas”, dijo Goodman. “¿Cuál fue el diagnóstico? Si no hubo un diagnóstico claro, ¿qué les llevó a pensar que se podría reiniciar el ensayo? Existe tanto interés y preocupación potencial acerca de una vacuna contra COVID-19 que cuanta más información se pueda proporcionar, más tranquilizador sería”.

La FDA deberá balancear los posibles riesgos de una vacuna experimental con el peligro que representa COVID-19, que ya ha matado a casi 200,000 estadounidenses.

“También hay consecuencias potenciales si detiene un estudio”, dijo Goodman.

Si la de AstraZeneca falla, el gobierno estadounidense está apoyando otras seis vacunas. Los problemas potenciales con la vacuna de AstraZeneca muestran que ésta es una inversión inteligente, dijo Adalja. “Te da un poco más de seguridad”.

Schaffner dijo que los científicos deben recordar que la investigación de vacunas es impredecible.

“Los investigadores de Oxford estuvieron diciendo este verano que iban a llegar primero”. “Pero esta es exactamente la razón por la que el doctor Anthony Fauci y el resto de nosotros hemos estado diciendo: ‘Nunca se sabe lo que sucederá una vez que comienzas los ensayos en humanos a gran escala’”.

Esta historia de KHN se publicó primero en California Healthline, un servicio de la California Health Care Foundation

Esta historia fue producida por Kaiser Health News, un programa editorial independiente de la Kaiser Family Foundation.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

USE OUR CONTENT

This story can be republished for free (details).

Readers and Tweeters Grapple With COVID Therapies and Forecasts

Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names.

Giving Convalescent Plasma a Shot

Used to effectively treat mumps, measles, and even the so-called Spanish flu in 1918, convalescent plasma may not be a silver bullet, but it still has the potential to play an important role in helping some patients recover from COVID-19 (“5 Things to Know About Convalescent Blood Plasma,” Aug. 27).

To support its recent decision, the Food and Drug Administration used data from previous use cases of convalescent plasma for other respiratory coronaviruses, results of early safety and efficacy trials in animal models, and published studies on the safety and efficacy of convalescent plasma before issuing Emergency Use Authorization (EUA). The agency also pointed to a Mayo Clinic preliminary analysis of 56,000 patients who were given high or low titer units of blood plasma.

[khn_slabs slabs=”241884″ view=”inline”]

The EUA also specifies that donor blood can be released only to hospitals and patients after it is tested with a currently available antibody test that accurately detects the right type of antibodies to neutralize the virus and confirms that the blood contains sufficient levels of these antibodies for treatment purposes. This means that less accurate, less specific tests that are more susceptible to false positives will not be used to identify COVID-19 convalescent plasma — something that should give patients higher confidence that the plasma they receive meets scientific and quality standards.

Dr. Fernando Chaves, a board-certified hematopathologist who serves as Global Head of Medical and Scientific Affairs at Ortho Clinical Diagnostics, Raritan, New Jersey

I’m quoted here saying what everybody already knows: if we want to know if plasma works, we need a trial.

This isn’t academic for me: I want to know if I should be using plasma in my patients with severe COVID-19. This fiasco was preventable. https://t.co/MjS2DXbYUX

— Adam W Gaffney (@awgaffney) August 28, 2020

— Dr. Andrew Gaffney, Boston

Vaccination and Prognostication

Both assertions that seniors will drive 800 miles or come home from an assisted living or skilled nursing facility to live with families are dubious (“What Seniors Can Expect as Their New Normal in a Post-Vaccine World,” Aug. 3). The latter are need-based moves (think dementia, wandering). The former makes sense for those who won’t tolerate the physical strain of long car rides — think Florida to D.C.

— Laurie Orlov, Aging and Health Technology Watch, Port St. Lucie, Florida

I wonder if many of these predictions are more likely to be true among those who have personal experience with COVID-19, either through personal experience with illness or loss of family or friends. https://t.co/uRZnuSfFLf via @khnews

— Rosemary Wright, PhD (@rwrightphd) August 3, 2020

— Rosemary Wright, Wichita, Kansas

I don’t want these precautions to last forever. I want there to be a time where we can all give each other hugs and high fives again. We were built to be together and celebrations bring us so much joy. I want there to be a time when we can all be in fun crowds again. I want to be able to smile out in public again and not have to cover my face. What do you think about all of this?

— Christopher DeCarlo, Oyster Bay, New York

We won’t go back to “the way things were” even after a vaccine for #COVID19 has been invented. This experience has been an opportunity to innovate and do better. Here are some changes you’re likely to see in #healthcare and beyond. https://t.co/l4x50qVxvM

— Tony Slonim MD, DrPH (@RenownCEOTonyMD) August 8, 2020

— Dr. Tony Slonim, Reno, Nevada

Humans as Guinea Pigs for the Sake of Corporate Piggy Banks?

We assume that this vaccine works, but how do we know (“They Pledged to Donate Rights to Their COVID Vaccine, Then Sold Them to Pharma,” Aug. 25)? The public is not some testing animal. I would not take this vaccine, especially since the back-and-forth is over money and not public health. No government should give any money to a business without a deal that protects the public as investors. We are not a source of free money; just as they make no concessions, we also should make no concessions without a deal. And the deal is public health.

There was no vaccine during the 1918-19 influenza, not until 1940. Our immune system needs to be considered as part of a cure. Is that not the theory behind flu shots? So, if we are exposed to the virus and allow our bodies to fight it off, that defense is greater than any vaccine. Those who cannot fight off the infection are the ones who need to be considered for medical attention — and not just some shot hopefully manufactured by a company that does not prioritize money over health.

There are times when profit is important, but since businesses are being subsidized, this is not one of those times. The world economy has been seriously affected, and printing money we do not have is not a sound idea. What good are medicine and doctors and medical research? Seems we should consider those old grandma medications, such as the hot toddy … whiskey and hot coffee and a good night to sweat it out under many covers. That cured my grandfather of influenza long before there was a vaccine.

Medical science doesn’t have all the answers. If soap can kill this coronavirus, then there must be a common household solution to eradicate it that is medically safe for humans. Perhaps technology students would do better to help the world instead of these money-hungry corporations.

— Tom Berger, Suffolk County, New York

Volunteers risk their lives in clinical trials, and the Oxford converted vaccine from public good to profitable commodity? …

They Pledged to Donate Rights to Their COVID Vaccine, Then Sold Them to Pharma https://t.co/vQw94BfxKE via @khnews

— Amar Jesani (@amarjesani) August 31, 2020

— Amar Jesani, Mumbai, India

On COVID Tests and Risk

I have worked in a clean lab for many decades. I know how to behave and how to take advantage of and handle PPE, for the purpose of achieving very low contamination levels. The article “Analysis: When Is a Coronavirus Test Not a Coronavirus Test?” (July 29) presents a false option. It is not about accepting a level of risk, it is about doing everything possible to reduce the risk.

In my labs, I had the ability to require adherence to careful procedures and the option to fire anyone who would not follow approved procedures. I don’t have that option with those who refuse to follow the simple instructions for COVID-19, including the “religious” wearing of a mask, the same way that women cover their heads when entering a Catholic church and Jewish men wear a yarmulke in a temple.

And when the president irresponsibly and criminally refuses to follow and to mandate simple instructions by medical experts, then I am unable to calculate the risk. I don’t think Ms. Rosenthal can calculate the level of risk she suggests we accept.

— Dimitri Papanastassiou, Pasadena, California

I enjoyed your piece, but I regret that you said so little about therapies that may emerge to help us. Vaccines are not the only hope. I think a disservice is being done by indicating that our only options are to live with it or wait for a vaccine.

— John Van Drie, North Andover, Massachusetts

Great article by @ahartreports. I too cringed initially at likening #covid19 to war but couldn’t agree more that we need to treat our #PublicHealthOfficials with respect and be grateful for their sacrifices https://t.co/rr9NT4tNlB via @khnews

— Meghan McGinty, PhD (@Breukelen299) September 1, 2020

— Meghan McGinty, Brooklyn, New York

The Hydroxy Paradox

Wouldn’t it be refreshing, instead of slamming other doctors’ practical experience with hydroxychloroquine at low dosages and supplemented with zinc, etc. at the first sign of the infection, to at least let them make fools of themselves (“Don’t Fall for This Video: Hydroxychloroquine Is Not a COVID-19 Cure,” July 31)? What is the harm?

Aren’t “we all in this together”? Why are we afraid of a difference in opinion? What if it really works using the protocols as stated? Let it play out. Pretty sure no one has died when prescribed “hydroxy” in low dosages by doctors in actual practice, unlike the deaths that occurred when given in massive dosages late in the infection.

Why make fun of doctors who are trying their best to help us all? That seems narrow-minded to me.

— Larry Koch, Agoura Hills, California

Reported this tweet. You are encouraging the use of a medication a. Without a license b. Without citing sources and c. Every double blind study has shown and increase in death.https://t.co/iN7eionH03https://t.co/eSPDwPz9V6

— Tara Tisch🦓🍀🎨🏴‍☠️ (@TaraTisch) August 22, 2020

— Tara Tisch, Peoria, Illinois

I know you disagree with Dr. Stella Immanuel, and that’s OK. The problem I have is that no one has done the clinical trials to prove that hydroxychloroquine doesn’t work. She said she has 350 patients who have had success with her prescriptions; the doctor from Dallas said she uses it with her own little concoction. If, in fact, what they are doing is working, then why don’t people visit these doctors to see if it is true — and, if it is, then try collaborating with them to keep people from dying, for crying out loud.

That is one of the problems here: Everyone is against one another instead of trying to support one another. We are Americans and, as in years past, we have stuck together for the betterment of the country. If we would stop trying to take care of America with money and start taking care of America with information, then America would live and thrive.

I am a first-year respiratory therapy student and spent 20 years in the Marine Corps, and back in the ’80s we took chloroquine, and I have no side effects and neither do the guys I stay in contact with. Keep in mind that the reports of the side effects are not in every patient and if hydroxychloroquine is offered to a patient and the patient is told, “This is going to make you better but there could be side effects later, but if you don’t take this you will get worse and we don’t know if you will die or not,” what do you think they will say? No one wants to die.

C’mon, let’s just be people trying to keep other people alive no matter the cost, no matter who is right or wrong — we can sort that out later.

— Jim Tumlinson, Canyon Lake, Texas

Editor’s note: A recent report from the Centers for Disease Control and Prevention expressed caution and concern that hydroxychloroquine was potentially being misused to treat COVID-19 and affecting supplies of the medication to treat rheumatoid arthritis, lupus and other conditions. “Current data on treatment and pre- or postexposure prophylaxis for COVID-19 indicate that the potential benefits of these drugs do not appear to outweigh their risks,” it said.

Yoga for All

I appreciate your article (“Namaste Noir: Yoga Co-Op Seeks to Diversify Yoga to Heal Racialized Trauma,” July 30) but have a hard time with “people of color” being repeated over and over. Yoga benefits all people, and until we start thinking as one and not labeling everything we will always have racial issues. We need to think all lives matter, not just a specific color. Thank you for your writings.

— Susan Ferguson, Cypress, California

“Namaste Noir” ?????????? good and important article, but really, really poor headline choice @KHNews https://t.co/GefI9Zkoy8

— Eli Imadali (@eliimadaliphoto) August 9, 2020

— Eli Imadali, Denver

#Namaste. Yoga and meditation are helping Ms. Grant deal with COVID-19, the loss of her son and racial stress. Lots of lessons here for all of us. @KHNews #Equality https://t.co/GnxZn4l7QF

— Jimmy Etheredge (@JimmyEtheredge) August 14, 2020

— Jimmy Etheredge, Atlanta

Words That Carry Weight

Thank you for calling attention to the challenges people with obesity face regarding risks of COVID-19 infections and the potential that vaccines may not be effective (“America’s Obesity Epidemic Threatens Effectiveness of Any COVID Vaccine,” Aug. 6). I would like to comment on how you refer to people with obesity. The Obesity Action Coalition, and other organizations focused on obesity, recommend using people-first language. An article about cancer does not refer to cancer people, nor does one on cardiovascular disease label individuals as heart disease people. The terms “obese people” and “morbid obesity” are stigmatizing. It is better to utilize people-first language as Dr. Timothy Garvey did at the end of the article. As a member of the Obesity Medicine Association as well as an obesity medicine specialist and educator, I work diligently with patients to overcome the bias and stigma that society imposes. Please be considerate of the use of language when referring to people with obesity.

— Dr. Nicholas Pennings, Raleigh, North Carolina

It is becoming more & more obvious that we would‘ve “saved” FAR more lives here if we had put all the mask shaming energy into getting people to lose weight. But that would be un-PC.

America’s Obesity Epidemic Threatens Effectiveness of Any COVID Vaccine https://t.co/wfbUz9JSB9

— John Ziegler (@Zigmanfreud) August 10, 2020

— John Ziegler, Los Angeles

As a sociologist researching weight stigma, I am appalled by the article by Sarah Varney suggesting obesity will undermine vaccine effectiveness. The article is full of stereotypes and misinformation. In the first place, it is Big Pharma’s fault vaccines aren’t made for fat people. It is beyond incompetence that any vaccine drugmakers come up with would be less effective for half the population. In the second place, many of the diseases fat folk allegedly have are caused by yoyo dieting and stigma. And there is no proof weight loss would make any vaccines more effective as most fat people are biochemically different than thin ones. This is a tone-deaf, fat-phobic article that serves only corporate interests.

— Sherie Sanders, Springfield, Illinois

Jail Outbreaks

My life and those of others are being put in danger by the San Bernardino County Sheriff’s Department (“COVID Runs Amok in 3 Detroit-Area Jails, Killing At Least 2 Doctors,” July 23). I’m in jail with health issues: asthma, prediabetes, vitamin D deficiency, high blood pressure, and may have a cancerous tumor and peripheral neuropathy. I’ve already been put on quarantine two times, once because a deputy who tested positive for COVID-19 had direct contact with me and the other because they put someone in the cell with me who was symptomatic for COVID-19. When being transported anywhere, they put chains on us that have been on many people and have not been cleaned. Then they chain multiple people together, not even knowing if a person has or is a carrier of the coronavirus. The social distancing was put in effect to protect the lives of people. The sheriff’s department is violating it, putting lives in danger and will continue to do so until they are stopped. To top it off, I am state property and not even supposed to be here. I don’t want to die or see anyone else die for being in jail and catching COVID-19. So can someone please help us all.

— LeAire Moore Sr., Adelanto, California

Lots of people ask me why I stay home most of the time, mask up, wash my hands, socially distance.

Why should I? I’m young. I’m healthy. I work out and eat right.

But, I have a mother.

This is why. ⬇️https://t.co/IlKPXmTu65

— Samuel Cook, III | CPT, CNC, USAW (@samueljcookiii) September 6, 2020

— Samuel Cook III, New Orleans

Correcting the Record on the Navajo Language

The article “Two Navajo Sisters Who Were Inseparable Died of COVID Just Weeks Apart” (Aug. 26) is incorrect. The Navajo language is most certainly “written down” and is taught in schools and universities.

— Randy Truman, Albuquerque

Editor’s note: Thanks for helping us clarify that point. The article has been updated.

Medicaid Expansion in the Age of COVID

The COVID-19 pandemic has shown us that Americans are in desperate need of health insurance, including publicly financed health insurance programs such as Medicaid. The time is now for some policymakers in America to reshape how they think of Medicaid as more than a government handout that makes us worse and not better.

Medicaid is a health insurance program that is jointly funded by the state and federal government. This program provides low-cost insurance to adults with low income, both young and elderly, pregnant women, the disabled and children through the Children’s Health Insurance Program, commonly known as the CHIP program.

The Affordable Care Act provided an opportunity for states to expand coverage to individuals at 138% of the federal poverty level. As an added incentive, the federal government pledged to pay 100% of the costs to expand, a share that would be reduced to 90% by 2020. In recent months, states such as Oklahoma and Missouri through the ballot box have expanded Medicaid. This leaves only 12 states to not expand, but millions more in need of affordable health insurance.

The argument by some policymakers against the Medicaid program is the fear of incentivizing Americans to not work. Contrary to this belief, in 2017, it was reported that more than 63% of Medicaid recipients are already in the workforce while only 7% were not working for various reasons.

Finally, since the beginning of the pandemic, one study estimated that nearly 27 million Americans could lose their employer-sponsored insurance this year. Of those 27 million, nearly 13 million would be eligible for Medicaid.

The American people deserve to have affordable health insurance. Therefore, policymakers have an obligation to expand it and not contract.

— Reginald Parson, Portland, Maine

This is happening right now throughout our system and its utterly disgusting and unacceptable.

Health Care Workers of Color Nearly Twice as Likely as Whites to Get #COVID-19 https://t.co/1VOFQid8mM via @khnews

— Stephen Ferrara, DNP (@StephenNP) August 6, 2020

— Stephen Ferrara, New York City

With No Legal Guardrails for Patients, Ambulances Drive Surprise Medical Billing

School librarian Amanda Brasfield bent over to grab her lunch from a small refrigerator and felt her heart begin to race. Even after lying on her office floor and closing her eyes, her heart kept pounding and fluttering in her chest.

The school nurse checked Brasfield’s pulse, found it too fast to count and called 911 for an ambulance. Soon after the May 2018 incident, Brasfield, now 39, got a $1,206 bill for the 4-mile ambulance ride across the northwestern Ohio city of Findlay — more than $300 a mile. And she was on the hook for $859 of it because the only emergency medical service in the city has no contract with the insurance plan she has through her government job.

More than two years later, what was diagnosed as a relatively minor heart rhythm problem hasn’t caused any more health issues for Brasfield, but the bill caused her some heartburn.

“I felt like it was too much,” she said. “I wasn’t dying.”

Brasfield’s predicament is common in the U.S. health care market, where studies show the majority of ambulance rides leave patients saddled with hundreds of dollars in out-of-network medical bills. Yet ground ambulances have mostly been left out of federal legislation targeting “surprise” medical bills, which happen when out-of-network providers charge more than insurers are willing to pay, leaving patients with the balance.

However, the COVID-19 pandemic has prompted temporary changes that could help some patients. For instance, ambulance services that received federal money from the CARES Act Provider Relief Fund aren’t allowed to charge presumptive or confirmed coronavirus patients the balance remaining on bills after insurance coverage kicks in. Also during the pandemic, the Centers for Medicare & Medicaid Services is letting Medicare pay for ambulance trips to destinations besides hospitals, such as doctors’ offices or urgent care centers equipped to treat recipients’ illnesses or injuries.

But researchers and patient advocates said consumers need more, and lasting, protections.

[khn_slabs slabs=”241884″ view=”inline” /]

 

“You call 911. You need an ambulance. You can’t really shop around for it,” said Christopher Garmon, an assistant professor at the University of Missouri-Kansas City who has studied the issue.

A Health Affairs study, published in April, found 71% of all ambulance rides in 2013-17 for members of one large, national insurance plan involved potential surprise bills. The median out-of-network surprise ground ambulance bill was $450, for a combined impact of $129 million a year.

And a study published last summer in JAMA Internal Medicine found 86% of ambulance rides to ERs — the vast majority by ground ambulances, not helicopters — resulted in out-of-network bills.

Caitlin Donovan, senior director of the National Patient Advocate Foundation in Washington, D.C., said she hears from consumers who get such bills and resolve to call Uber the next time they need to get to the ER. Although experts — and Uber — agree an ambulance is the safest option in an emergency, research out of the University of Kansas found that the Uber ride-sharing service has reduced per-person ambulance use by at least 7%.

Only Ambulance in Town

When Brasfield was rushed to the hospital, her employer, Findlay City Schools, offered insurance plans only from Anthem, and none included the Hanco EMS ambulance service in its network. School system treasurer Michael Barnhart said the district couldn’t insist that Hanco participate. Starting Sept. 1, Barnhart said the school system will have a different insurer, UMR/United Healthcare, but the same plans.

“There is no leverage when they are the only such service around. If it were a particular medical procedure, we could encourage employees to seek another doctor or hospital even if it was further away,” Barnhart said in an email. “But you can’t encourage anyone to use an ambulance service from 50 miles away.”

There is great disagreement about what an ambulance ride is worth.

Brasfield’s insurer paid $347 for her out-of-network ambulance ride. She said Anthem representatives told her that was consistent with in-network rates and Hanco’s $1,206 charge was simply too high.

Jeff Blunt, a spokesperson for Anthem, said that 90% of ambulance companies in Ohio agree to Anthem’s payment rates; Hanco is among the few medical transport providers that don’t participate in its network. He said Anthem reached out to Hanco twice to negotiate a contract but never heard back.

Brasfield sent three letters appealing Anthem’s decision and called Hanco to negotiate the bill down. The companies wouldn’t budge. Hanco sent her a collections notice.

An Ohio school librarian took a 4-mile ambulance ride across Findlay, Ohio, to nearby Blanchard Valley Hospital for what turned out to be a relatively minor heart rhythm problem. But the trip led to a $1,206 ambulance bill.

Rob Lawrence of the American Ambulance Association pointed out that nearly three-quarters of the nation’s 14,000 ambulance providers have low transport volumes but need to staff up even when not needed, creating significant overhead. And because of the pandemic, ambulance providers have seen reduced revenue, higher costs and more uncompensated care, the association’s executive director, Maria Bianchi, said in an email.

Officials at Blanchard Valley Health System, which owns Hanco, said Brasfield’s ambulance charge was on par with the national average for this type of medical emergency, in which EMTs started an IV line and set up a heart monitor.

Fair Health, a nonprofit that analyzes billions of medical claims, estimates an ambulance ride costs $408 in-network and $750 out-of-network in Toledo, which is about 50 miles away from Findlay and has several ambulance companies. Even the higher of those two costs is $456 less than Brasfield’s bill.

Widespread Problem, No Action

Similar stories play out across the nation.

Ron Brooks, 72, received two bills of more than $690 each when his wife had to be rushed about 6 miles to a hospital in Inverness, Florida, after two strokes in November 2018. The only ambulance service in the county, Nature Coast EMS, was out-of-network for his insurer, Florida Blue. Neither had responded to requests for comment by publication time. Brooks’ wife died, and it took him months to pay off the bills.

“There should be an exception if there was no other option,” he said.

Sarah Goodwin of Shirley, Massachusetts, got a $3,161 bill after her now-14-year-old daughter was transported from a hospital to another facility about an hour away after a mental health crisis in November. That was the balance after her insurer, Tricare Prime, paid $491 to Vital EMS. Despite reaching out to the ambulance company and her insurer, she received a call from a collection agency.

“I feel bullied,” she said earlier this year. “I don’t plan to pay it.”

Since KHN asked the companies questions about the bill and the pandemic began, she said, she hadn’t gotten any more bills or calls as of late August.

In an emailed response to KHN, Vital EMS spokesperson Tawnya Silloway said the company wouldn’t discuss an individual bill, and added: “We make every effort to take patients out of the middle of billing matters by negotiating with insurance companies in good faith.”

Last year, an initial attempt at federal legislation to ban surprise billing left out ground ambulances. This February, a bill was introduced in the U.S. House that calls for an advisory committee of government officials, patient advocates and representatives of affected industries to study ground ambulance costs. The bill remains pending, without any action since the pandemic began.

In the meantime, consumer advocates suggest patients try to negotiate with their insurers and the ambulance providers.

Michelle Mello, a Stanford University professor who specializes in health law and co-authored the JAMA Internal Medicine study that examined surprise ambulance bills, was able to appeal to her insurer to pay 90% of such a bill she got after a bike accident last year.

That tactic, however, proved futile for Brasfield, the Ohio librarian. She set up a $100-a-month payment plan with Hanco and, eventually, paid off the bill.

From now on, she said, she’ll think twice about taking an ambulance unless she feels her life is in imminent danger. For anything less, she said, she’d ask a relative or friend to drive her to the hospital.

Lights, Camera, No Action: Insurance Woes Beset Entertainment Industry Workers

Before the coronavirus pandemic shut down the entertainment industry in March, Jeffrey Farber had a steady flow of day jobs in film and television, including work on “Hunters” and “Blue Bloods.” But when theaters, movies and TV shows stopped production, not only did Farber lose his acting income, he also stopped accruing the hours and earnings he needed to qualify for health insurance through his labor union, SAG-AFTRA.

Without the acting jobs, his insurance would be ending this month.

When the pandemic halted film and television production, Jeffrey Farber lost his acting income and stopped accruing the hours and earnings he needed to qualify for health insurance through his labor union, SAG-AFTRA.

“This is an unbelievable situation,” said Farber, 65, a survivor of pancreatic cancer. “There are going to be so many people who aren’t going to be able to make it.”

From Broadway to Hollywood, many actors, directors, backstage workers, musicians and others in the performing arts face similar coverage suspensions. Those in the entertainment industry often have several employers over the course of a year as they move from show to show. In some ways, they’re quintessential gig workers.

Their employers generally make financial contributions to a benefit fund under the terms of the union contract. And the workers pay premiums on their coverage. If workers accumulate a predetermined number of hours or earnings, they can qualify for coverage for up to a year. Coverage is typically comprehensive and quite inexpensive. Farber paid just $408 every three months to cover him and his husband.

It’s a model some academics think might work for others in the gig economy. “It makes coverage possible in industries like retail, construction and entertainment where it might not otherwise be offered,” said JoAnn Volk, a research professor at Georgetown University’s Center on Health Insurance Reforms.

[khn_slabs slabs=”241887″ view=”inline” /]

As the COVID pandemic period has shown, it doesn’t always work well. Someone in the entertainment industry may be able to weather a dry spell without any work because he’s already qualified for coverage based on past employment. But once coverage lapses, this system could leave entertainers at a disadvantage over other workers returning to a more conventional job, where coverage can start immediately. Plus, members may continue to owe union dues, even though they aren’t eligible for health benefits.

The timing of the shutdown couldn’t be worse for Farber, who needed just 12 days of work or $249 in earnings by the end of June to qualify for continued coverage in October. Accumulating that would have been “easy as pie,” he said.

In the entertainment unions’ benefit plans, “coverage is always prospective,” said Phyllis Borzi, a former assistant secretary in the Department of Labor who headed the Employee Benefits Security Administration and is now a consultant. “That works fine if you have a short interruption, but they’ve been out so long, to the extent they have hours banked, they must be out of them by now.”

SAG-AFTRA represents about 160,000 professionals in TV, radio, film and other media. The union requires that members this year generally must accumulate at least 84 days of qualifying work or earn $18,040 over four quarters to be eligible for coverage for the next four quarters.

Farber eventually got a temporary reprieve because he learned he could qualify for coverage with lower earnings under a separate category for people who are least 40 years old and have 10 or more years of health plan eligibility. But he doesn’t know how coverage changes planned for next year will affect his eligibility.

The health plan has taken some steps to alleviate concerns raised by members. In April, it cut health care premiums in half for the second quarter and this month announced a temporary reduction of COBRA premiums for some members.

The SAG-AFTRA benefit fund didn’t respond to requests for comment.

Even in the best of times, it can be difficult for those in the entertainment industry whose names appear in small print in the credits to string together enough work to qualify for coverage. If social restrictions were to ease and people could get work heading into fall, any accumulated hours and income may be too far in the past to count toward future coverage, leaving them no choice but to start accumulating them all over again.

In contrast, when employers hire someone eligible for on-the-job coverage, they typically can’t impose waiting periods longer than 90 days for health insurance under the Affordable Care Act.

Like people who work for a single employer, workers who lose coverage through their union benefit plan can continue their coverage for up to 18 months under federal COBRA law, but workers who make that choice generally have to pick up the entire cost of the plan. And COBRA coverage is not cheap. They may also enroll in a plan on their state marketplace set up by the Affordable Care Act or, if they qualify, in Medicaid, the federal-state program for low-income people.

When the pandemic hit in mid-March, Dee Nichols had logged 512 of the 600 hours he needed to accumulate in a six-month period to qualify for health coverage with the Motion Picture Industry health plan.

“You’re trying to fill a tub of water and it keeps getting holes,” says Dee Nichols, a camera operator in Los Angeles. “They’re fine with guys like me contributing and then not being able to pull [benefits] out of it. It drives me insane.”Nichols, a camera operator in Los Angeles who is a member of Local 600 of the International Cinematographers Guild, had two shows lined up in early March that would have brought him up to the threshold by March 21, the end of his qualifying period for coverage. Then production was canceled.

It wasn’t the first time that Nichols, 49, had missed the hours target for coverage through his union plan. “You’re trying to fill a tub of water and it keeps getting holes,” Nichols said. Meanwhile, he pays $400 a month for an individual marketplace plan with a $6,000 deductible. “They’re fine with guys like me contributing and then not being able to pull [benefits] out of it,” he said. “It drives me insane.”

The Motion Picture Industry health plan also offered some relief to members, including extending them some hours of credit, waiving premiums for dependents and offering COBRA subsidies.

But the assistance didn’t help Nichols qualify for coverage.

He and another member are part of a class action lawsuit arguing that the health plan has a responsibility under federal law to treat all plan participants equally.

The health plan didn’t respond to a request for comment.

Unclear When ‘We’ll Work Again’

To assist its members during the pandemic, the Actors’ Equity Association health plan waived premiums for three months starting in May and is temporarily offering a lower-cost plan through the end of the year.

But since these multi-employer plans are self-funded, they pay members’ claims directly. That can cause problems when work is scant and employers aren’t paying into the fund.

“All of these health funds have different financial positions, and they have to maintain reserves in order to maintain coverage for their members,” said Brandon Lorenz, communications director of the Actors’ Equity Association, which represents approximately 52,000 actors and stage managers.

SAG-AFTRA, which has projected a $141 million deficit in its health plan this year, announced far-reaching changes to coverage for next year, including higher thresholds on earnings and days worked to qualify for coverage.

That could prove an added challenge for Jeffrey Farber, who is concerned about what job opportunities will be available when the industry recovers.

“None of us knows when production is going to start again or if we’ll work again,” he said.

Luz, cámara… sin acción: problemas con el seguro de salud en Hollywood por COVID

Antes que la pandemia paralizara la industria del entretenimiento en marzo, Jeffrey Farber tenía un flujo constante de trabajo en cine y televisión, incluyendo apariciones en “Hunters” y “Blue Boods”.

Pero cuando se cancelaron las producciones teatro, cine y TV, Farber no sólo perdió sus ingresos como actor, sino que también dejó de acumular las horas y ganancias que necesitaba para calificar para el seguro médico a través de su sindicato, SAG-AFTRA.

Sin estos trabajos en actuación, su seguro terminaría en septiembre.

“Es una situación increíble”, dijo Farber, de 65 años y sobreviviente de cáncer de páncreas. “Va a haber mucha gente que no va a poder vivir así”.

Desde Broadway hasta Hollywood, muchos actores, directores, trabajadores de producción, músicos y otros se enfrentan a situaciones similares. Los trabajadores en la industria del entretenimiento a menudo tienen varios empleadores en el transcurso de un año, a medida que pasan de un espectáculo a otro. En cierto modo, son trabajadores por cuenta propia.

Sus empleadores generalmente hacen contribuciones financieras a un fondo de beneficios bajo los términos del contrato del sindicato. Y los trabajadores pagan primas por su cobertura.

Si acumulan un número predeterminado de horas o ganancias, pueden calificar para la cobertura por un año. La cobertura suele ser amplia y bastante económica. Farber pagaba sólo $408 cada tres meses para él y su esposo.

Es un modelo que algunos académicos piensan que podría funcionar para otros en este tipo de industria. “Hace posible la cobertura en sectores como la venta al por menor, la construcción y el entretenimiento donde de otra manera no se ofrecería”, señaló JoAnn Volk, investigadora del Centro de Reformas del Seguro de Salud de la Universidad Georgetown.

Pero como ha mostrado este tiempo de pandemia, no siempre funciona bien. Alguien en la industria del entretenimiento puede ser capaz de  sobrellevar un período de sequía, sin trabajo, porque califica para la cobertura basada en un empleo anterior.

Pero una vez que la cobertura caduca, este sistema podría dejar a los artistas en desventaja sobre otros trabajadores que regresan a un trabajo más convencional, donde la cobertura puede comenzar inmediatamente. Además, los miembros pueden seguir debiendo cuotas sindicales, aunque no sean elegibles para los beneficios de salud.

El momento del cierre no podría ser peor para Farber, que sólo necesitaba 12 días de trabajo o $249 en ingresos, a fines de junio, para calificar para la continuidad de la cobertura en octubre.

En los planes de los sindicatos del entretenimiento, “la cobertura siempre es prospectiva”, explicó Phyllis Borzi, ex secretaria adjunta del Departamento de Trabajo que dirigió la Administración de Seguridad de Beneficios del Empleado y que ahora es consultora. “Eso funciona bien si tienes una interrupción corta, pero han estado sin trabajo tanto tiempo, que si tuvieran horas acumuladas, ya las habrían perdido”.

SAG-AFTRA representa a unos 160,000 profesionales de la televisión, la radio, el cine y otros. El sindicato exige que los miembros de este año deberían acumular al menos 84 días de trabajo calificado o ganar $18,040 en cuatro trimestres para tener derecho a la cobertura de los próximos cuatro trimestres.

Farber finalmente obtuvo un aplazamiento temporal porque se enteró que podía calificar para la cobertura, con menores ingresos, en una categoría separada para las personas que tienen al menos 40 años y 10 o más de elegibilidad para el plan de salud. Pero no sabe cómo los cambios de cobertura planeados para el próximo año afectarán su elegibilidad.

El plan de salud ha tomado algunas medidas para aliviar las preocupaciones planteadas por los miembros. En abril, redujo las primas de atención médica a la mitad para el segundo trimestre y en septiembre anunció una reducción temporal de las primas de COBRA para algunos miembros.

El fondo de beneficios SAG-AFTRA no respondió a las solicitudes de comentarios.

Al igual que las personas que trabajan para un solo empleador, los trabajadores que pierden la cobertura de su plan de beneficios del sindicato pueden continuar su cobertura hasta 18 meses bajo la ley federal COBRA, pero los trabajadores que toman esa decisión generalmente tienen que pagar el costo total del plan.

Y la cobertura de COBRA no es barata. También pueden inscribirse en un plan en el mercado de su estado establecido por ACA o, si califican, en Medicaid, el programa federal-estatal para personas de bajos ingresos.

Cuando la pandemia golpeó a mediados de marzo, Dee Nichols había registrado 512 de las 600 horas que necesitaba acumular, en un período de seis meses, para calificar para la cobertura de salud con el plan de salud de la Industria Cinematográfica.

Nichols, un operador de cámara de Los Angeles que es miembro del Local 600 del International Cinematographers Guild, tenía programados dos contratos a principios de marzo que le habrían permitido alcanzar el umbral para el 21 de marzo, el final de su período de calificación para la cobertura. Pero la producción se canceló.

El plan de salud de la Industria Cinematográfica también ofreció cierto alivio a los miembros, incluyendo la extensión de algunas horas de crédito, la renuncia a las primas para los dependientes y la oferta de subsidios para COBRA.

Pero la asistencia no ayudó a Nichols a calificar para la cobertura.

Él y otro miembro forman parte de una demanda colectiva que argumenta que el plan de salud tiene la responsabilidad, según la ley federal, de tratar a todos los participantes por igual.

El plan de salud no respondió a una solicitud de comentarios.

No está claro cuándo “Volveremos a trabajar”

Para ayudar a sus miembros durante la pandemia, el plan de salud de la Actors’ Equity Association renunció a las primas durante tres meses a partir de mayo y ofrece, temporalmente, un plan de menor costo hasta fin de año.

Pero como estos planes de varios empleadores se autofinancian, pagan los reclamos de los miembros directamente. Eso puede causar problemas cuando el trabajo es escaso y los empleadores no pagan al fondo.

“Todos estos fondos de salud tienen diferentes capacidades financieras, y deben mantener reservas para preservar la cobertura de sus miembros”, explicó Brandon Lorenz, director de comunicaciones de la Actors’ Equity Association, que representa a aproximadamente 52,000 actores y directores.

SAG-AFTRA, que ha proyectado un déficit de $141 millones en su plan de salud este año, anunció cambios de gran alcance en la cobertura para el próximo año, incluyendo umbrales más altos en las ganancias y días trabajados para calificar para la cobertura.

Esto podría ser un desafío adicional para Jeffrey Farber, quien está preocupado por las oportunidades de trabajo que estarán disponibles cuando la industria se recupere.

“Nadie sabe cuándo se reanudarán las producciones o si volveremos a trabajar”, señaló.

Esta historia fue producida por Kaiser Health News, un programa editorial independiente de la Kaiser Family Foundation.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

USE OUR CONTENT

This story can be republished for free (details).